



ABN 53 075 582 740

PRESS RELEASE
2 March 2015

Bionomics begins trading on OTCQX marketplace

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced its ordinary shares commenced trading on the OTCQX marketplace in the U.S., effective March 2, 2015.

The move allows Bionomics to provide new and existing US investors with immediate access to trade its ordinary shares in US dollars during US market hours. It also enables the company to maintain its commitment to providing regular disclosure in line with the reporting requirements of Bionomics' primary market, the Australian Securities Exchange (ASX).

OTCQX offers transparent trading in established, investor-focused US companies and global companies listed on a qualified stock exchange in their home country.

"We are pleased to welcome Bionomics to OTCQX," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "Trading on OTCQX enables Bionomics to provide its US investors transparent trading and convenient access to its news and disclosure so they can more easily analyse, value and trade its securities. We look forward to working with Bionomics as they continue to build shareholder value."

"We have seen growing interest from US investors in Bionomics joining the OTCQX marketplace – a logical move that will provide new opportunities for the company," said Dr. Deborah Rathjen, Bionomics' CEO and Managing Director.

Bionomics is among a leading group of global issuers enabling their ordinary shares that trade on the ASX to also trade and settle in the US. As the Company's advisor and principal American liaison Cowen and Company, LLC, advised on the establishment of the global share structure to better facilitate US settlement and deposit of the Company's shares with the Depository Trust Company (DTC).

US investors now have direct market access on the OTCQX under the symbol BNOEF to hold Bionomics ordinary shares on deposit in their US brokerage account, removing transaction costs associated with holding shares offshore. Cowen is also responsible for guidance on the Company's OTCQX requirements and arranging a comprehensive suite of US capital markets services.

"We are very pleased to be working with Bionomics to make the best of its OTCQX listing," said Chris Weekes, Managing Director and Head of the International Markets Group at Cowen.

Investors can find current financial disclosure and Real-Time Level 2 Quotes for Bionomics on www.otcmarkets.com.

Financial disclosure and other information about the company are also available at www.bionomics.com.au.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+61 (0)8 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications

Rudi Michelson
+61 (0)3 9620 3333
rudim@monsoon.com.au

Stern IR

Beth DelGiacco
+1 (212) 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO; OTCQX: BNOEF) is a biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co.

www.bionomics.com.au

About Cowen and Company

Cowen and Company offers comprehensive investment banking services, including equity, equity-linked and debt financings and mergers and acquisitions advisory services. In addition, we offer our clients access to world-class research, as well as institutional sales and trading services. Drawing upon the depth of our research and industry knowledge, we specialize in the key areas of growth in our economy. Our industry sector expertise includes Health Care, Technology, Media & Telecommunications, Consumer, Energy, Metals and Mining, Aerospace & Defense and Transportation. In addition, we offer extensive and focused aftermarket trading services as a leading market maker in our target sectors. For more information regarding Cowen, please visit www.cowen.com

About OTCQX

OTCQX is the best marketplace for established, global and growth companies operated by OTC Markets Group. To qualify for the OTCQX marketplace, companies must meet high financial standards, demonstrate compliance with U.S. securities laws, be current in their disclosure, and be sponsored by a professional third-party advisor. The companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications. For more information, please visit www.otcmarkets.com.

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, BNC210, BNC101, our acquisitions of Eclipse Therapeutics and Prestwick Chemical, and ability to develop products from their platform, its licensing deals with Merck & Co, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a

downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors' products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.